Loading...
The recombinant herpes zoster vaccine (Shingrix) has been authorized for use in immunocompromised patients since 2021, but observational evidence has suggested it may be associated with autoimmune disease exacerbations. A new industry-supported, randomized trial looked at the effect of the vaccine on disease activity in nearly 1200 adults (median age, 50) with autoimmune rheumatic diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis) who were on stable doses of immunosuppressive medications (see ). Participants, recruited from a tertiary specialty center in Brazil, were assigned to receive two doses of recombinant zoster vaccine or placebo. Disease activity was assessed at 6 and 12 weeks by …